Physician profile
David A Duncan
NPI 1427041656
$1,667.84
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $279 · 2021: $72.98 · 2024: $30.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $309.20 | 2019-2020 | |
| Amgen INC. | $261.36 | 2019-2024 | Uplizna |
| Lilly USA, LLC | $244.23 | 2019-2020 | |
| Grifols USA, LLC | $197.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.41 | 2019 | |
| Medtronic Vascular, INC. | $129.07 | 2019 | |
| Novo Nordisk INC | $81.16 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $55.38 | 2019 | |
| Horizon Therapeutics Plc | $52.31 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $36.17 | 2020 | |
| Amarin Pharma, INC. | $29.33 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.24 | 2019 | |
| Abbvie INC. | $27.84 | 2021 | |
| Genentech USA, INC. | $24.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.12 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.